AbbVie Inc. (ABBV)
USD 173.02
(-1.35%)
USD 173.02
(-1.35%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 46.57 Billion USD | -13.87% |
| 2022 | 54.07 Billion USD | -19.22% |
| 2021 | 66.93 Billion USD | -13.75% |
| 2020 | 77.6 Billion USD | 189.54% |
| 2019 | 26.8 Billion USD | -18.83% |
| 2018 | 33.02 Billion USD | 17.66% |
| 2017 | 28.06 Billion USD | -11.58% |
| 2016 | 31.74 Billion USD | 36.4% |
| 2015 | 23.27 Billion USD | 249.27% |
| 2014 | 6.66 Billion USD | 29.93% |
| 2013 | 5.12 Billion USD | -47.52% |
| 2012 | 9.77 Billion USD | 35654.18% |
| 2011 | -27.48 Million USD | -184.96% |
| 2010 | -9.64 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 57.5 Billion USD | 2.81% |
| 2024 Q1 | 55.93 Billion USD | 20.1% |
| 2024 Q3 | 63.82 Billion USD | 10.99% |
| 2023 Q1 | 55.38 Billion USD | 2.43% |
| 2023 Q2 | 52.25 Billion USD | -5.64% |
| 2023 FY | 46.57 Billion USD | -13.87% |
| 2023 Q3 | 47.45 Billion USD | -9.18% |
| 2023 Q4 | 46.57 Billion USD | -1.87% |
| 2022 Q2 | 64.41 Billion USD | -4.4% |
| 2022 FY | 54.07 Billion USD | -19.22% |
| 2022 Q4 | 54.07 Billion USD | -6.41% |
| 2022 Q3 | 57.77 Billion USD | -10.3% |
| 2022 Q1 | 67.37 Billion USD | 0.65% |
| 2021 Q1 | 75.77 Billion USD | -2.36% |
| 2021 FY | 66.93 Billion USD | -13.75% |
| 2021 Q2 | 73.59 Billion USD | -2.88% |
| 2021 Q3 | 68.53 Billion USD | -6.87% |
| 2021 Q4 | 66.93 Billion USD | -2.34% |
| 2020 Q2 | 81.41 Billion USD | 214.3% |
| 2020 Q3 | 79.16 Billion USD | -2.76% |
| 2020 Q4 | 77.6 Billion USD | -1.97% |
| 2020 FY | 77.6 Billion USD | 189.54% |
| 2020 Q1 | 25.9 Billion USD | -3.36% |
| 2019 Q2 | 32.08 Billion USD | -0.49% |
| 2019 Q4 | 26.8 Billion USD | -3.42% |
| 2019 FY | 26.8 Billion USD | -18.83% |
| 2019 Q1 | 32.24 Billion USD | -2.34% |
| 2019 Q3 | 27.75 Billion USD | -13.51% |
| 2018 Q2 | 33.56 Billion USD | 18.68% |
| 2018 FY | 33.02 Billion USD | 17.66% |
| 2018 Q4 | 33.02 Billion USD | 1.62% |
| 2018 Q3 | 32.49 Billion USD | -3.19% |
| 2018 Q1 | 28.28 Billion USD | 0.77% |
| 2017 Q3 | 29.34 Billion USD | -5.78% |
| 2017 Q4 | 28.06 Billion USD | -4.37% |
| 2017 Q1 | 32.21 Billion USD | 1.48% |
| 2017 Q2 | 31.14 Billion USD | -3.3% |
| 2017 FY | 28.06 Billion USD | -11.58% |
| 2016 Q1 | 24.35 Billion USD | 4.66% |
| 2016 FY | 31.74 Billion USD | 36.4% |
| 2016 Q3 | 31.09 Billion USD | -1.35% |
| 2016 Q4 | 31.74 Billion USD | 2.09% |
| 2016 Q2 | 31.51 Billion USD | 29.4% |
| 2015 Q2 | 23.72 Billion USD | 222.02% |
| 2015 FY | 23.27 Billion USD | 249.27% |
| 2015 Q1 | 7.36 Billion USD | 10.57% |
| 2015 Q4 | 23.27 Billion USD | 1.61% |
| 2015 Q3 | 22.9 Billion USD | -3.45% |
| 2014 Q3 | 7.07 Billion USD | 25.08% |
| 2014 Q4 | 6.66 Billion USD | -5.8% |
| 2014 Q2 | 5.65 Billion USD | -9.75% |
| 2014 Q1 | 6.26 Billion USD | 22.19% |
| 2014 FY | 6.66 Billion USD | 29.93% |
| 2013 FY | 5.12 Billion USD | -47.52% |
| 2013 Q1 | 8.05 Billion USD | -17.53% |
| 2013 Q2 | 6.01 Billion USD | -25.35% |
| 2013 Q3 | 5.83 Billion USD | -3.01% |
| 2013 Q4 | 5.12 Billion USD | -12.1% |
| 2012 FY | 9.77 Billion USD | 35654.18% |
| 2012 Q4 | 9.77 Billion USD | 453.9% |
| 2012 Q3 | -2.76 Billion USD | -3604.18% |
| 2012 Q2 | -74.53 Million USD | -81.8% |
| 2012 Q1 | -40.99 Million USD | -49.18% |
| 2011 FY | -27.48 Million USD | -184.96% |
| 2011 Q4 | -27.48 Million USD | 0.0% |
| 2010 FY | -9.64 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bristol-Myers Squibb Company | 30 Billion USD | -55.237% |
| Bristol-Myers Squibb Company Ce | 30 Billion USD | -55.237% |
| Johnson & Johnson | 7.47 Billion USD | -523.19% |
| Eli Lilly and Company | 22.4 Billion USD | -107.844% |
| Merck & Co., Inc. | 29.35 Billion USD | -58.626% |
| Novartis AG | 12.95 Billion USD | -259.483% |
| Organon & Co. | 8.06 Billion USD | -477.303% |
| Pfizer Inc. | 72.18 Billion USD | 35.487% |